

Table S1. Randomized placebo-controlled trials of biologic therapy in moderate-severe ulcerative colitis.

Study (year)	Biological drug	Patients	Sample size	Follow up	Main results.	Conclusion
ACT 1 and 2 (2005) [156]	IFX	Anti-TNFs naïve	364 patients	ACT 1: 54 weeks ACT 2: 30 weeks	<i>Clinical response at week 8:</i> ACT 1: 69% IFX 5 mg vs 61% IFX 10 mg vs 37% placebo; p <0.001 ACT 2: 64% IFX 5 mg vs 69% IFX 10 mg vs 29% placebo; p <0.001 <i>Clinical response at week 54:</i> ACT 1: 45% IFX 5 mg vs 44% IFX 10 mg vs 20% placebo; p <0.001	IFX is superior to placebo
ULTRA 1 (2011) [79]	ADA	Anti-TNFs naïve	390 patients	ULTRA 1: 8 weeks	<i>Clinical remission at week 8:</i> 18.5% ADA vs 9.2% placebo; p =0.031 <i>Clinical remission in bio-naïve at week 8:</i> 21.3% ADA vs 11% placebo; p =0.017	ADA is superior to placebo
ULTRA 2 (2012) [157]		59.7% anti-TNFs naïve	494 patients	ULTRA 2: 52 weeks	<i>Clinical remission in bio-naïve at week 52:</i> 22% ADA vs 12.4% placebo; p =0.029	
PURSUIT (2014) [158,159]	GOL	Anti-TNFs naïve	774 patients (phase 3) 464 patients	6 weeks (induction) 54 weeks (maintenance)	<i>Clinical response at week 6:</i> 51.8% GOL 200/100 mg vs 29.7% placebo; p <0.0001 <i>Clinical response at week 54:</i> 47.0% GOL 50 mg vs 49.7% GOL 100 mg vs 31.2% placebo; p =0.010 and p <0.001 <i>Clinical remission and mucosal healing at week 54:</i> 41.7% GOL 50 mg vs 42.4% GOL 100 mg vs 26.6% placebo; p =0.002	GOL is superior to placebo
GEMINI (2013) [160]	VDZ	51.8% anti-TNFs naïve	895 patients	52 weeks	<i>Clinical response at week 6:</i> 47.1% VDZ vs 25.5% placebo (p<0.001) <i>Clinical remission at week 52:</i> 41.8% VDZ vs 15.9% placebo; p<0.001	VDZ is superior to placebo
UNIFI (2019) [47]	UST	46.1% anti-TNFs naïve	961 patients	44 weeks	<i>Clinical remission at week 8:</i> 15.5% UST vs 5.3% placebo; p<0.001 <i>Clinical remission at week 44:</i> 38.4% UST/12 weeks vs 43.8% UST/8weeks vs 24% placebo; p=0.002 and p<0.001	UST is superior to placebo